Table 2.
Baseline characteristics of patients treated with T-DXd
| Study | n | Period of enrollment | Age, years, median (range) | Asian, n (%) | HR+, n (%) | Metastasis | ECOG 0, n (%) |
|---|---|---|---|---|---|---|---|
| DESTINY-01, 2019 | 184 | 2017-2018 | 55.0 (28.0-96.0) | 63 (34.2) | 97 (52.7) | Visceral 91.8%/CNS 13.0% | 102 (55.4) |
| DESTINY-02, 2022 | 406 | 2018-2020a | 54.2 (22.4-88.5) | 112 (27.6) | 238 (58.6) | Visceral 77.8%/CNS 18.2% | 228 (56.2) |
| DESTINY-03, 2022 | 261 | 2018-2020 | 54.3 (27.9-83.1) | 152 (58.2) | 131 (50.2) | Visceral 70.4%/CNS 16.4% | 154 (59.0) |
| DESTINY-04, 2022 | 374 | 2019b-2021 | 57.5 (31.5-80.2) | 151 (40.5) | 333 (89.3) | Liver 71.3%/lung 32.2%/CNS 6.4% | 200 (53.6) |
| DESTINY-07, 2022 | 23 | 2020c-2023d | NA | NA | NA | NA | NA |
| TUXEDO-1, 2022 | 15 | 2020-2021 | 69 (30-76) | 0 (0) | 12 (80) | Visceral 80.0%/CNS 100.0% | 9 (60.0) |
| DEBBRAH, 2022 | 21 | 2020-2021 | 53.0 (36.0-77.0) | 0 (0) | 16 (76.2) | Non-CNS 76.2%/CNS 100% | 15 (71.4) |
| DAISY, 2021 | 179 | 2019-2021 | 55 (24-82) | 0 (0) | NA | NA | NA |
| Modi et al., 20209 | 54 | 2016-2018 | 56.6 (33-75) | 27 (50.0) | 47 (87.0) | Bone 63%/visceral 100%/CNS 9.3% | 36 (66.7) |
| Shimomura et al., 202312 | 51 | 2018e | 56 (31-79) | 51 (100) | 43 (84.3) | NA | 31 (60.8) |
| Tamura et al., 201910 | 115 | 2015-2018 | 55.0 (47.0-66.0) | 62 (54.0) | 81 (70) | NA | 72 (63) |
| DE-REAL, 2023 | 143 | 2020-2023 | 66 (33-84) | 0 (0) | 108 (75) | NA | NA |
| Nakajima et al., 202226 | 22 | 2020-2021 | 59.5 (42-78) | 22 (100) | 15 (68.2) | Bone 68.2%/CNS 40.9% | 6 (27.3) |
| TREX-Old, 2023 | 27 | 2021-2023 | 74 (70-81) | 0 (0) | NA | Visceral 70.0% | 6 (22) |
| ROSET-BM, 2022 | 104 | 2015-2021 | NAf | 104 (100) | 59 (56.7) | Visceral 76.0%/CNS 100% | 27 (26.0) |
CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; HR+, hormone receptor positive; NA, not available; T-DXd, trastuzumab deruxtecan.
a
The recruitment was completed on 7 January 2021 (https://clinicaltrials.gov/ct2/show/NCT03523585).
b
The first patient was enrolled on 27 December 2018.
c
The first patient was enrolled on 28 December 2020.
d
The recruitment is ongoing.
e
The first patient was enrolled on 26 December 2017.
f
Twenty-nine patients (27.9%) with age ≥65 years.